News: WuXi PharmaTech (Cayman) Inc. (WX.N)

WX.N on New York Stock Exchange

16.52USD
4:03pm EST
Price Change (% chg)

$-0.42 (-2.48%)
Prev Close
$16.94
Open
$17.00
Day's High
$17.05
Day's Low
$16.40
Volume
148,100
Avg. Vol
348,961
52-wk High
$18.00
52-wk Low
$3.67

view news for:
Select another date:

Thu, Sep 3 2009

China's drug contractors on a fast-growth track

NEW YORK, Sept 3 (Reuters) - Companies that conduct research for drugmakers are poised for torrid growth in China as their multinational clients look to sell more medicines in the world's most populous country and cut development costs.

HEADLINE STOCKS-Some U.S. stocks on the move on Aug. 12

(Updates to afternoon trading, adds Mindray Medical, WuXi, Commercial Vehicle, Ethan Allen. AstraZeneca/Forest Labs, ADC Telecommunications. Delta/US Airways)

US RESEARCH SUMMARY-Non-S&P 500 March 27 1713 GMT

RTRS

 Following is a summary of research actions on non-S&P 500 companies reported

US RESEARCH SUMMARY-Non-S&P 500 March 27 1454 GMT

RTRS

 Following is a summary of research actions on non-S&P 500 companies reported

ADR Report-GE, drugs and banks lift foreign stocks

NEW YORK, March 12 (Reuters) - Overseas shares traded in the United States rose on Thursday as S&P's downgrade of General Electric's debt rating was perceived as good news and a pharmaceutical takeover sent drug makers' ADRs higher.

US-RESEARCH/ (NON-S&P500)

Lecg UBS Cuts to neutral from buy; price

US-RESEARCH/ (NON-S&P500)

--------------------------------------------------------------- - ----------- Werner Enterprises Credit Suisse Starts with underperform rating; price target $18; reports

WuXi shares drop as Covance China JV falls through

BANGALORE (Reuters) - Shares of WuXi PharmaTech , China's biggest pharmaceutical research outsourcing firm, fell 21 percent to a 52-week low after the company and clinical testing firm Covance Inc parted ways on a joint venture to provide preclinical contract research services in China.

WuXi shares drop as Covance China JV falls through

BANGALORE (Reuters) - Shares of WuXi PharmaTech , China's biggest pharmaceutical research outsourcing firm, fell 21 percent to a 52-week low after the company and clinical testing firm Covance Inc parted ways on a joint venture to provide preclinical contract research services in China.

Providence Equity hires HK-based managing director

SHANGHAI, Sept 16 (Reuters) - Providence Equity Partners will hire General Atlantic Managing Director Sean Tong as a managing director in Hong Kong as it moves to bolster dealmaking opportunities in China, the U.S. buyout firm said on Tuesday.

Select another date:
view news for: